MLA
APRE icon

MB, Levis & Associates’s Aprea Therapeutics APRE Stock Holding History

MB, Levis & Associates’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-806
Closed -$1.19K – 247
2025
Q3 		$1.19K Hold
806
– – ﹤0.01% 229
2025
Q2 		$1.36K Hold
806
– – ﹤0.01% 248
2025
Q1 		$1.64K Hold
806
– – ﹤0.01% 254
2024
Q4 		$2.65K Hold
806
– – ﹤0.01% 252
2024
Q3 		$2.22K Hold
806
– – ﹤0.01% 256
2024
Q2 		$3.28K Hold
806
– – ﹤0.01% 238
2024
Q1 		$5.39K Hold
806
– – ﹤0.01% 214
2023
Q4 		$3.79K Hold
806
– – ﹤0.01% 225
2023
Q3 		$3.36K Hold
806
– – ﹤0.01% 229
2023
Q2 		$2.54K Buy
+806
New +$3K ﹤0.01% 243

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MB, Levis & Associates's APRE Position: Q4 2025 in Review

MB, Levis & Associates sold out of Aprea Therapeutics (APRE) in Q4 2025, closing a stake of 806 shares — an estimated $1.19K sold.

MB, Levis & Associates first reported a position in APRE in Q2 2023 and held it in 10 quarters. The position peaked at $5.39K in Q1 2024. 22 funds tracked by Wall St. Rank hold APRE as of Q4 2025.

  • MB, Levis & Associates reported no remaining Aprea Therapeutics position as of Q4 2025 after selling out during the quarter.
  • MB, Levis & Associates sold 806 Aprea Therapeutics shares in Q4 2025, an estimated $1.19K.
  • MB, Levis & Associates first reported a position in Aprea Therapeutics in Q2 2023 and held it in 10 quarters.
  • MB, Levis & Associates's Aprea Therapeutics position peaked at $5.39K in Q1 2024.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2025.

Based on MB, Levis & Associates's 13F filing for Q4 2025, filed 14 Jan 2026.